cardiac monitoring system News
-
Medicalgorithmics Announces Hiring of Medical Device Commercial Veteran James Landis as Vice President Sales and Business Development of North America
Medicalgorithmics a Warsaw Stock Exchange listed medical technology company, is boosting its sales capabilities in North America with appointment of James Landis as the new Vice President of Sales and Business Development for North America. The move is aimed at accelerating long-term growth and increasing market share in the US. James brings 20 years of extensive experience in sales and ...
-
Coala Life launches first direct-to-patient telecardiology service
Coala Life, the award-winning Swedish innovator of real-time remote cardiac monitoring solutions announces the launch of Coala Connect Rx. This new service is offered in the US via an online prescription process in partnership with leading cardiologists. Following a telemedicine-based prescription, a Coala Heart Monitor is shipped directly to the patients’ home, and patient education is ...
-
iRhythm announces results of four studies to be unveiled at American Heart Association Scientific Sessions
iRhythm Technologies will have the results of four studies presented by leading clinical investigators at the American Heart Association’s 2022 Scientific Sessions on Nov. 5-7 in Chicago, Illinois. The studies listed below focus on iRhythm’s core suite of Zio XT and AT patch-based extended and mobile cardiac monitoring products and services. Saturday, Nov. 5 3:00 – 4:00 p.m. ...
-
iRhythm builds case for wearable cardiac monitor with data in fainting, TAVR patients
iRhythm Technologies has presented new data on its Zio wearable cardiac monitoring device at the American College of Cardiology (ACC) 71st Annual Scientific Session & Expo, building the clinical case for its devices. One study used Zio AT for monitoring patients who were taken to hospital after fainting. By using the device to monitor patients after discharge, the physicians reduced ...
-
Biotricity to launch commercial sales of its disruptive cardiac monitoring device, Biotres in April 2022
Biotricity Inc. (NASDAQ:BTCY) (“Biotricity” or the “Company”), a medical diagnostic and consumer healthcare technology company, will officially launch the commercial sales of its FDA cleared, wireless wearable cardiac monitoring device, Biotres, in April 2022. The product has been available for pre-orders to physicians, medical offices, hospitals and individual use since ...
-
Biotricity now taking pre-orders for its Biotres wireless wearable cardiac monitoring device
Announcement follows FDA clearance Pre-Orders begin on February 23, 2022 with units shipping April 1, 2022 Biotricity Inc. (NASDAQ:BTCY) (“Biotricity” or the “Company”), a medical diagnostic and consumer healthcare technology company, today announced that it is now taking pre-orders for Biotres, the Company’s three-lead device designed to continuously record ...
-
Biotricity receives FDA 510(k) clearance for its Biotres Cardiac Monitoring Device
Biotres is designed to continuously record ECG data for early detection of cardiac arrhythmias The Biotres addresses the $2 Billion-dollar holter market Biotricity Inc. (NASDAQ:BTCY) (“Biotricity” or the “Company”), a medical diagnostic and consumer healthcare technology company, today reported it has received 510(k) clearance from the U.S. Food and Drug ...
-
Assessing Heart Function and Fluid Status with Cardiac Scales: Interview with John Lipman, CEO, and Corey Centen, Founder, Bodyport
Bodyport, a medtech company based in San Francisco, developed the Bodyport Cardiac Scale, a set of weighing scales that can non-invasively assess fluid status and heart function. The scales can detect these signals through the feet when a patient steps onto the device. The technology is intended to be convenient and requires only 20 seconds each morning, and should easily lend itself to ...
-
Bardy Diagnostics Announces CE Mark Certification for 14-Day Carnation Ambulatory Monitor (CAM™) Patch in Europe and Expansion of Home Enrollment Program Amidst COVID-19 Crisis
SEATTLE, May 26, 2020 /PRNewswire/ — Bardy Diagnostics, Inc., (“BardyDx”), a leading provider of ambulatory cardiac monitoring technologies and custom data solutions, announced today it received CE mark certification for the 14-Day version of the Carnation Ambulatory Monitor (“CAM”) patch, the industry’s only P-wave centric ambulatory cardiac patch monitor and ...
-
Bardy Diagnostics Announces Use of The Carnation Ambulatory Monitor Patch to Measure QT Segments in COVID-19 Patients Using Hydroxychloroquine
Seattle, WA — March 25, 2020 — Bardy Diagnostics, Inc., (“BardyDx”), a leading provider of ambulatory cardiac monitoring technologies and custom data solutions, announced today that its Carnation Ambulatory Monitor (“CAM™”) Patch has been chosen for use in protocols to measure QT Segments in COVID-19 patients who have been prescribed Hydroxychloroquine ...
-
Medicomp Inc. Partners to Monitor Covid-19 Patients
Medicomp, Inc., a technology leader in remote and wireless cardiac monitoring, is pleased to announce a strategic partnership with New York based Lenox Hill Hospital, part of the Northwell Health system. Located in the epicenter of the US coronavirus pandemic, Lenox Hill Hospital will be using Medicomp’s TelePatch™ mobile cardiac telemetry (MCT) monitor to measure the heart’s ...
-
HSC Partners with CardiacSense for medical-grade wearables
CardiacSense is a leading manufacturer of a range of wearable devices for the continuous monitoring of heart arrhythmias and blood pressure HSC signs exclusive Distribution Agreement for Australia & New Zealand for watches & wristbands HomeStay to integrate CardiacSense solutions in HSC’s IoT Platform for assistive technology HomeStay Care Limited (ASX: HSC) ...
By CardiacSense
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you